The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion
Abstract
Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (AMPK). Whether metformin or the satiety factor leptin, which also stimulates AMPK in muscle, regulates this enzyme in pancreatic islets is unknown. We have recently shown that forced increases in AMPK activity inhibit insulin secretion from MIN6 cells (da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, and Rutter GA. Biochem J 371: 761–774, 2003). Here, we explore whether 1) glucose, metformin, or leptin regulates AMPK activity in isolated islets from rodent and human and 2) whether changes in AMPK activity modulate insulin secretion from human islets. Increases in glucose concentration from 0 to 3 and from 3 to 17 mM inhibited AMPK activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells. Incubation with metformin (0.2–1 mM) activated AMPK in both human islets and MIN6 β-cells in parallel with an inhibition of insulin secretion, whereas leptin (10–100 nM) was without effect in MIN6 cells. These studies demonstrate that AMPK activity is subject to regulation by both glucose and metformin in pancreatic islets and clonal β-cells. The inhibitory effects of metformin on insulin secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 3×
“(58) showed that metformin activates AMPK in rat hepatocytes and skeletal muscle, an effect that may account for the effect of metformin on increased muscle glucose transport, decreased hepatic glucose output, and beneficial blood lipid profile (12).”
BackgroundOWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“It is likely that metformin, which is positively charged at physiological pH, needs to accumulate inside mitochondria as much as 1,000-fold (39) to exert these actions.”
BackgroundLeptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053 · cited 3×
“Because leptin has recently been shown to activate AMPK in skeletal muscle (35), it seemed important here to determine the effects of this hormone on AMPK activity and insulin secretion in pancreatic -cells.”
BackgroundBailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · cited 2×
“(58) showed that metformin activates AMPK in rat hepatocytes and skeletal muscle, an effect that may account for the effect of metformin on increased muscle glucose transport, decreased hepatic glucose output, and beneficial blood lipid profile (12).”
BackgroundTriggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201 · cited 1×
“In addition, KATP channel-independent “amplifying” effects may also contribute to the stimulation of release independently of changes in intracellular Ca(2) concentration (20).”
BackgroundPharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173 · cited 1×
“Moreover, basal and glucose-stimulated insulin plasma levels are consistently decreased in metformintreated patients (11), an observation usually attributed to the increase in peripheral insulin sensitivity (41).”
BackgroundHayashi, T., Hirshman, M. F., Kurth, E. J., Winder, W. W., & Goodyear, L. J. (1998) · Diabetes · doi:10.2337/diabetes.47.8.1369 · Cited by 774
Cited by
AMP-activated protein kinase signaling in metabolic regulation
Long, Y. C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29044 · Cited by 1,098
Metabolic Signaling in Fuel-Induced Insulin Secretion
Prentki, M., Matschinsky, F. M., & Madiraju, S. R. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.018 · Cited by 548
“Thus, acute activation of AMPK by the insulin sensitizers pioglitazone andmetformin decreases GIIS (Lamontagne et al., 2009; Leclerc et al., 2004).”
BackgroundAMPK: a metabolic gauge regulating whole-body energy homeostasis
Lage, R., Diéguez, C., Vidal-Puig, A., & López, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.007 · Cited by 505
Dzeja, P., & Terzic, A. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10041729 · Cited by 475
AMPK inhibition in health and disease
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., & Andreelli, F. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.488215 · Cited by 383
Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer
Fogarty, S., & Hardie, D. G. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.09.012 · Cited by 350
AMPK as a mediator of hormonal signalling
Lim, C. T., Kola, B., & Korbonits, M. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0063 · Cited by 298
Maida, A., Lamont, B. J., Cao, X., & Drucker, D. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1937-z · Cited by 294
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Viollet, B. (2009) · Frontiers in Bioscience · doi:10.2741/3460 · Cited by 278
Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo
Sun, W., Lee, T.-S., Zhu, M., Gu, C., Wang, Y., Zhu, Y., & Shyy, J. Y.-J. (2006) · Circulation · doi:10.1161/circulationaha.106.630194 · Cited by 264
Metformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
Effects of rosiglitazone and metformin on pancreatic beta cell gene expression
Richardson, H., Campbell, S. C., Smith, S. A., & Macfarlane, W. M. (2006) · Diabetologia · doi:10.1007/s00125-006-0155-1 · Cited by 34
Glucose plus metformin compared with glucose alone on β-cell function in mouse pancreatic islets
HASHEMITABAR, M., BAHRAMZADEH, S., SAREMY, S., & NEJADDEHBASHI, F. (2015) · Biomedical Reports · doi:10.3892/br.2015.476 · Cited by 21
Metadata
- Authors
- Leclerc, I., Woltersdorf, W. W., da Silva Xavier, G., Rowe, R. L., Cross, S. E., Korbutt, G. S., Rajotte, R. V., Smith, R., & Rutter, G. A.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2004-06
- Volume
- 286
- Issue
- 6
- Pages
- E1023-E1031
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2168180935
- Cited by
- 173
- References
- 16
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.